AvenCell Europe GmbH
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.avencell.com
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
- Conditions
- Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
- Interventions
- Other: Cyclophosphamide (Non-IMP, Lymphodepletion)Other: Fludarabine (Non-IMP, Lymphodepletion)Drug: Allo-RevCAR01-T
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 80
- Registration Number
- NCT05949125
- Locations
- 🇩🇪
Klinikum der Universität München, Munich, Bavaria, Germany
🇩🇪Universitätsklinikum Marburg, Marburg, Hessen, Germany
🇩🇪Universitätsklinikum Köln, Köln, Germany
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
- Conditions
- Prostate Cancer
- Interventions
- Drug: UniCAR02-T-pPSMADrug: UniCAR02-T (IMP)
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 16
- Registration Number
- NCT04633148
- Locations
- 🇩🇪
Universitätsklinikum Dresden, Dresden, Sachsen, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 90
- Registration Number
- NCT04230265
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
🇩🇪Klinikum der Universität München, Munich, Bavaria, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
- Conditions
- Renal CancerNon-small Cell Lung CancerProstate CancerTransitional Cell Carcinoma
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 23
- Registration Number
- NCT03927573
- Locations
- 🇩🇪
Klinikum rechts der Isar der TU München, Munich, Bayern, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
🇩🇪Universitätsklinikum Marburg, Marburg, Hessen, Germany
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
- Conditions
- Relapsed AMLRefractory AMLAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT03516760
- Locations
- 🇩🇪
Klinikum rechts der Isar, München, Bayern, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
🇩🇪Universitätsklinikum Dresden, Dresden, Sachsen, Germany